This major cap biotech company borke its major support at $150.
Now it acts like resistance.
ENTERING with tier1 here with STOP above $150 and will ADD through $144 for a poential move to April's lows at $134-$136 (first TARGET)
IBB (biotech ETF) looks very weak.
Now it acts like resistance.
ENTERING with tier1 here with STOP above $150 and will ADD through $144 for a poential move to April's lows at $134-$136 (first TARGET)
IBB (biotech ETF) looks very weak.
